TD Cowen raised the firm’s price target on Procept BioRobotics to $75 from $65 and keeps a Buy rating on the shares. The firm noted they unveiled its vision to become a leading global urology company during its investor event at AUA. The clinical value proposition of Aquablation therapy in BPH was showcased along with the potential for the therapy to fill an unmet clinical need in low and intermediate risk prostate cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics Engages Investors with Company Insights
- Procept BioRobotics price target raised to $72 from $63 at Truist
- Procept BioRobotics price target raised to $67 from $57 at Wells Fargo
- Procept BioRobotics price target raised to $64 from $53 at Leerink
- Procept BioRobotics sees FY24 revenue $213.5M, consensus $210.18M